3 Dividend Growth Stocks to Buy and Never Sell

In This Article:

The power of dividend growth investing lies in one simple truth: Companies that consistently raise their dividends have historically outperformed the broader market since 1900. These elite businesses combine robust revenue growth, strong fundamentals, and shareholder-friendly management teams.

The greatest dividend growth stories share common traits: durable competitive advantages, reasonable payout ratios, and proven records of execution. When these qualities align with disciplined dividend reinvestment, the magic of compounding can generate substantial long-term wealth.

Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free ?

Three companies stand out as exceptional long-term dividend growth investments worth holding forever. Each company has demonstrated an unwavering commitment to shareholder returns while maintaining leadership positions in their respective industries.

A makeshift sign that reads dividends.
Image source: Getty Images.

Read on to find out more about these three incredible dividend growth stocks.

Building wealth one membership at a time

Costco Wholesale (NASDAQ: COST) has mastered a deceptively simple retail model -- charging membership fees for access to high-quality goods at rock-bottom prices. Though its 0.52% dividend yield appears modest, Costco's 17.92% five-year dividend growth rate and conservative 26.3% payout ratio signal substantial room for future increases.

Costco is trading at a forward price-to-earnings ratio of 50, and investors pay a premium for this quality growth story. This premium is justified by consistent membership fee income and pricing power that generate predictable cash flow in any economic environment.

The forever-hold case for Costco stems from its industry-leading 90% worldwide membership renewal rate and vast international growth runway. With only a third of its stores currently outside the U.S., Costco can replicate its proven model globally for decades while rewarding shareholders through growing dividends.

A pharmaceutical innovator hitting its stride

AbbVie (NYSE: ABBV) continues to demonstrate its prowess in navigating the challenging landscape of drug development and patent cliffs. The stock offers an attractive 3.27% dividend yield and has delivered a solid 7.69% five-year dividend growth rate.

While AbbVie's eye-catching 202.6% payout ratio may be worrisome, it's important to bear in mind that the industry average is 141%, reflecting the cyclical nature of drug development.

Trading at a forward price-to-earnings ratio of 15.8, AbbVie's shares trade at a significant discount to the broader market represented by the S&P 500. What's more, the company's dominance in immunology is continuing with Skyrizi and Rinvoq already generating multibillion-dollar revenue, effectively countering Humira's patent expiration.